WO1998045331A3 - Anti-vegf antibodies - Google Patents

Anti-vegf antibodies Download PDF

Info

Publication number
WO1998045331A3
WO1998045331A3 PCT/US1998/006604 US9806604W WO9845331A3 WO 1998045331 A3 WO1998045331 A3 WO 1998045331A3 US 9806604 W US9806604 W US 9806604W WO 9845331 A3 WO9845331 A3 WO 9845331A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
vegf antibodies
antibodies
inhibit
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/006604
Other languages
French (fr)
Other versions
WO1998045331A2 (en
Inventor
Manuel Baca
James A Wells
Leonard G Presta
Henry B Lowman
Yvonne Man-Yee Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998045331(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/908,469 external-priority patent/US6884879B1/en
Priority to JP54292298A priority Critical patent/JP3957765B2/en
Priority to DE69836729T priority patent/DE69836729T2/en
Priority to SI9830876T priority patent/SI0973804T1/en
Priority to HK00102696.3A priority patent/HK1023577B/en
Priority to BRPI9809387A priority patent/BRPI9809387B8/en
Priority to KR1019997009194A priority patent/KR100794454B1/en
Priority to CA002286330A priority patent/CA2286330C/en
Priority to DE200712000021 priority patent/DE122007000021I1/en
Priority to AU71007/98A priority patent/AU743758B2/en
Priority to IL13224098A priority patent/IL132240A0/en
Priority to DK98917991T priority patent/DK0973804T3/en
Priority to BRPI9816350A priority patent/BRPI9816350B8/en
Priority to EP98917991A priority patent/EP0973804B1/en
Priority to NZ500078A priority patent/NZ500078A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of WO1998045331A2 publication Critical patent/WO1998045331A2/en
Publication of WO1998045331A3 publication Critical patent/WO1998045331A3/en
Priority to NO19994869A priority patent/NO324264B1/en
Priority to IL132240A priority patent/IL132240A/en
Anticipated expiration legal-status Critical
Priority to CY2005008C priority patent/CY2005008I2/en
Priority to IL175906A priority patent/IL175906A/en
Priority to LU91320C priority patent/LU91320I2/en
Priority to CY20071100358T priority patent/CY1106382T1/en
Priority to NL300278C priority patent/NL300278I2/en
Priority to LTPA2007004C priority patent/LTC0973804I2/en
Priority to CY200700012C priority patent/CY2007012I1/en
Priority to NO2007015C priority patent/NO2007015I1/en
Priority to NO2007014C priority patent/NO2007014I2/en
Priority to NO2017039C priority patent/NO2017039I2/en
Priority to NO2019045C priority patent/NO2019045I1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Air Bags (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)

Abstract

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro, and inhibit tumor growth in vivo.
PCT/US1998/006604 1997-04-07 1998-04-03 Anti-vegf antibodies Ceased WO1998045331A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
CA002286330A CA2286330C (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
NZ500078A NZ500078A (en) 1997-04-07 1998-04-03 Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
IL13224098A IL132240A0 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
SI9830876T SI0973804T1 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
HK00102696.3A HK1023577B (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
BRPI9809387A BRPI9809387B8 (en) 1997-04-07 1998-04-03 humanized anti-human vascular endothelial growth factor antibody and composition comprising it
KR1019997009194A KR100794454B1 (en) 1997-04-07 1998-04-03 Anti-VEF antibody
JP54292298A JP3957765B2 (en) 1997-04-07 1998-04-03 Anti-VEGF antibody
DE200712000021 DE122007000021I1 (en) 1997-04-07 1998-04-03 Anti-vefg Antibodies
AU71007/98A AU743758B2 (en) 1997-04-07 1998-04-03 Anti-VEGF antibodies
DE69836729T DE69836729T2 (en) 1997-04-07 1998-04-03 ANTI-VEFG ANTIBODIES
DK98917991T DK0973804T3 (en) 1997-04-07 1998-04-03 Anti-VEGF antibodies
BRPI9816350A BRPI9816350B8 (en) 1997-04-07 1998-04-03 isolated nucleic acid, vector, host cell, as well as process for producing a humanized anti-vegf antibody
EP98917991A EP0973804B1 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
IL132240A IL132240A (en) 1997-04-07 1999-10-06 Anti-vegf antibodies
NO19994869A NO324264B1 (en) 1997-04-07 1999-10-06 Anti-VEGF antibody, composition, nucleic acid, vector, host cell, method and drug for medical use.
CY2005008C CY2005008I2 (en) 1997-04-07 2005-04-21 ANTI-VEGF ANTIBODIES
IL175906A IL175906A (en) 1997-04-07 2006-05-24 Anti-vegf antibodies with stronger binding affinity
LU91320C LU91320I2 (en) 1997-04-07 2007-02-28 Ranibizumab and its pharmaceutically acceptable derivatives (LUCENTIS)
CY20071100358T CY1106382T1 (en) 1997-04-07 2007-03-14 ANTI-VEGF ANTIBODIES
NL300278C NL300278I2 (en) 1997-04-07 2007-03-26 Anti-VEGF antibodies
LTPA2007004C LTC0973804I2 (en) 1997-04-07 2007-04-04 Anti-VEGF antibodies
CY200700012C CY2007012I1 (en) 1997-04-07 2007-04-05 ANTI-VEGF ANTIBODIES
NO2007014C NO2007014I2 (en) 1997-04-07 2007-12-20 Anti-VEGF antibody, composition, nucleic acid, vector, host cell, method and drug for medical use
NO2007015C NO2007015I1 (en) 1997-04-07 2007-12-20 ranibizumab
NO2017039C NO2017039I2 (en) 1997-04-07 2017-08-01 Bevacizumab - prolonged SPC
NO2019045C NO2019045I1 (en) 1997-04-07 2019-12-11 Ranibizumab - Prolonged SPC

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07
US08/833,504 1997-04-07
US08/908,469 1997-08-06
US08/908,469 US6884879B1 (en) 1997-04-07 1997-08-06 Anti-VEGF antibodies

Publications (2)

Publication Number Publication Date
WO1998045331A2 WO1998045331A2 (en) 1998-10-15
WO1998045331A3 true WO1998045331A3 (en) 1998-12-03

Family

ID=27125626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006604 Ceased WO1998045331A2 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies

Country Status (25)

Country Link
US (2) US7060269B1 (en)
EP (4) EP1325932B9 (en)
JP (1) JP3957765B2 (en)
KR (2) KR100816621B1 (en)
CN (1) CN100480269C (en)
AT (2) ATE293640T1 (en)
AU (1) AU743758B2 (en)
BR (1) BRPI9809387B8 (en)
CA (1) CA2286330C (en)
CY (3) CY2005008I2 (en)
DE (5) DE69836729T2 (en)
DK (2) DK1325932T5 (en)
ES (2) ES2273415T3 (en)
FR (2) FR05C0020I2 (en)
GE (1) GEP20105118B (en)
IL (1) IL132240A0 (en)
LT (1) LTPA2005005I1 (en)
LU (2) LU91167I2 (en)
NL (2) NL300193I2 (en)
NO (3) NO324264B1 (en)
NZ (1) NZ500078A (en)
PT (1) PT1325932E (en)
SI (1) SI1325932T1 (en)
TR (1) TR199903123T2 (en)
WO (1) WO1998045331A2 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US8945580B2 (en) 2007-07-11 2015-02-03 Ibio Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US8951791B2 (en) 2003-02-03 2015-02-10 Ibio, Inc. System for expression of genes in plants
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US9012199B2 (en) 2003-05-22 2015-04-21 Ibio, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US9115201B2 (en) 2008-09-28 2015-08-25 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
US9487809B2 (en) 2010-05-28 2016-11-08 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US9487589B2 (en) 2011-06-30 2016-11-08 Genentech, Inc. Anti-c-met-antibody formulations
US9579390B2 (en) 2012-11-12 2017-02-28 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9983213B2 (en) 2008-07-23 2018-05-29 Roche Diagnostics Operations, Inc. Identification of subjects being susceptible to anti-angiogenesis therapy
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
USRE47194E1 (en) 2007-05-08 2019-01-08 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US10179925B2 (en) 2012-09-19 2019-01-15 Genentech, Inc. Compositions for preventing norleucine misincorporation into proteins
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10602739B2 (en) 2014-07-09 2020-03-31 Genentech, Inc. PH adjustment to improve thaw recovery of cell banks
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11273171B2 (en) 2013-07-12 2022-03-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11590235B2 (en) 2013-09-08 2023-02-28 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US11814425B2 (en) 2006-04-07 2023-11-14 Eye Point Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US11820816B2 (en) 2017-12-29 2023-11-21 Hoffman-La Roche Inc. Anti-VEGF antibodies and methods of use
US11945837B2 (en) 2011-12-22 2024-04-02 Genentech, Inc. Ion exchange membrane chromatography
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer

Families Citing this family (468)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
KR100816621B1 (en) 1997-04-07 2008-03-24 제넨테크, 인크. Anti-VEGF Antibodies
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
DK1140173T4 (en) * 1998-12-22 2013-06-10 Genentech Inc Vascular endothelial cell growth factor antagonists and applications thereof
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2463879C (en) * 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
KR20120068769A (en) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
DK2314629T4 (en) 2002-07-18 2023-02-06 Merus Nv RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
UA101945C2 (en) * 2003-05-30 2013-05-27 Дженентек, Инк. Treatment of cancer using bevacizumab
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
DK3095793T3 (en) 2003-07-28 2020-05-25 Genentech Inc Reduction of leaching of protein A during a protein A affinity chromatography
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
FR2859725B1 (en) * 2003-09-16 2006-03-10 Neovacs HIGH EFFICIENCY PROCESS FOR OBTAINING HUMAN ANTIBODIES THAT NEUTRALIZE THE BIOLOGICAL ACTIVITY OF A HUMAN CYTOKINE
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
CN101072797B (en) 2004-03-12 2012-05-09 瓦斯基因治疗公司 Antibodies that bind EPHB4, inhibit angiogenesis and tumor growth
DK1730196T3 (en) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-binding antibodies to inhibit antiogenesis and tumor growth
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
SI1771474T1 (en) * 2004-07-20 2010-06-30 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007000891A (en) 2004-07-23 2007-04-18 Genentech Inc Crystallization of antibodies or fragments thereof.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
PT1802334E (en) * 2004-10-21 2012-11-28 Genentech Inc Method for treating intraocular neovascular diseases
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP1833512A1 (en) * 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ES2633574T3 (en) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations
JP4875064B2 (en) * 2005-04-15 2012-02-15 シェーリング コーポレイション Methods and compositions for treating or preventing cancer
WO2006138690A2 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
PL2135881T3 (en) * 2005-06-20 2012-02-29 Genentech Inc Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
KR100877824B1 (en) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ＥＰＦ ＵＣＰ-ＶＨＬ interaction and its uses
WO2007059195A1 (en) * 2005-11-14 2007-05-24 University Of Southern California Integrin-binding small molecules
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
CA2630839C (en) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
BRPI0706840A2 (en) 2006-01-05 2011-04-05 Genentech Inc polynucleotide isolated anti-ephb4 antibodies, vector, host cell, method for producing an anti ephb4 antibody, method for producing an anti ephb4 immunoconjugate, method for detecting ephb4, method for diagnosing a composition disorder, method for inhibiting angiogenesis, method for treating a cancer, tumor and / or cell proliferation disorder and use of an antibody
SI1976884T1 (en) 2006-01-20 2013-04-30 Genetech, Inc. Anti-ephrinb2 antibodies and methods using same
BRPI0707733B1 (en) 2006-02-13 2019-12-31 Ibio, Inc. isolated antigen, vaccine composition, use of said composition and method for producing an antigen protein
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
CN101405030B (en) * 2006-03-22 2013-03-13 霍夫曼-拉罗奇有限公司 Use of an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2 in preparing kit for tumor therapy
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007233237A1 (en) * 2006-03-29 2007-10-11 Genentech, Inc. Diagnostics and treatments for tumors
EP2029159A2 (en) * 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
EP2068877A4 (en) 2006-07-19 2011-09-21 Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
CN100448892C (en) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 Antitumour vascular endothelial growth factor receptor VEGF-R antigen and its coding gene and application
CL2007002404A1 (en) 2006-08-21 2008-04-18 Hoffmann La Roche USE OF AN ANTI-VEGF ANTIBODY (VASCULAR ENDOTELIAL GROWTH FACTOR) FOR THE TREATMENT OF A PATIENT WHO SUFFERS A POSITIVE CANCER HER2 DURING OR AFTER TREATMENT WITH AN ANTI-HER2 ANTIBODY.
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
DK2457929T3 (en) 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
JP2010507594A (en) * 2006-10-20 2010-03-11 シェーリング コーポレイション Fully human anti-VEGF antibodies and methods of use
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
RU2474585C2 (en) 2007-01-22 2013-02-10 Дженентек, Инк. Precipitating and purifying proteins with polyelectrolytes
JP2010517944A (en) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー DLL4 signaling inhibitor and use thereof
MX2009008430A (en) 2007-02-09 2009-10-28 Genentech Inc Anti-robo4 antibodies and uses therefor.
JP5745840B2 (en) 2007-05-17 2015-07-08 ジェネンテック， インコーポレイテッド Inhibition of tumor metastasis by anti-neuropilin 2 antibody
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
KR102055873B1 (en) 2007-07-09 2019-12-13 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
ES2533266T5 (en) * 2007-10-30 2018-04-18 Genentech, Inc. Purification of antibodies by cation exchange chromatography
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
KR20100090683A (en) 2007-11-09 2010-08-16 제넨테크, 인크. Activin receptor-like kinase-i antagonist compositions and methods of use
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
EP2604279A1 (en) * 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
BRPI0914251B1 (en) 2008-06-25 2022-07-19 Novartis Ag RECOMBINANT IMMUNOLIGIANT, ITS ANTIGEN-BINDING FRAGMENT, USE THEREOF, AND COMPOSITION
CN102149825B (en) * 2008-07-08 2015-07-22 Abbvie公司 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
BRPI0823046B1 (en) 2008-08-14 2021-12-14 Genentech, Inc METHOD FOR PURIFYING A MONOCLONAL ANTIBODY FROM A COMPOSITION COMPRISING THE MONOCLONAL ANTIBODY AND AT LEAST ONE CHINESE HAMSTER OVARY PROTEIN (CHOP)
CN102137939A (en) * 2008-08-29 2011-07-27 霍夫曼-拉罗奇有限公司 Diagnosis and treatment of tumors independent of VEGF
JP2012502030A (en) 2008-09-05 2012-01-26 デューク ユニバーシティー Anti-lipid antibody
CN103599541A (en) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 Compositions and methods for the prevention of oxidative degradation of proteins
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP5913980B2 (en) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド Immunoglobulin variants and uses thereof
BRPI0921469B1 (en) 2008-11-03 2022-01-18 Molecular Partners Ag BINDING PROTEINS THAT INHIBIT INTERACTION WITH THE VEGF-A RECEPTOR, PHARMACEUTICAL COMPOSITION
DK2540843T3 (en) 2008-11-05 2014-09-01 Genentech Inc Genetic polymorphisms in age-related macular degeneration
DK2361085T4 (en) 2008-11-22 2018-10-08 Hoffmann La Roche USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
JP2012511929A (en) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン Stirred tank reactor and method
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
BRPI0918211A2 (en) 2008-12-23 2015-12-08 Genentech Inc patient identification methods, patient responsiveness prediction methods, monitoring methods, therapeutic efficacy optimization methods, and p1gf expression level detection kit
RU2636046C2 (en) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
WO2010081838A2 (en) 2009-01-14 2010-07-22 Novartis Ag Sterile prefilled container
JP2012517434A (en) 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション How to treat vascular lesions
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
PE20120835A1 (en) * 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES
AR076344A1 (en) * 2009-04-20 2011-06-01 Genentech Inc METHOD OF COMPLEMENTARY THERAPY AGAINST CANCER
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
PE20120902A1 (en) 2009-05-08 2012-08-08 Genentech Inc HUMANIZED ANTI-EGFL7 ANTIBODIES
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
JP5925677B2 (en) 2009-06-15 2016-06-01 アイコン・ジェネティクス・ゲーエムベーハー Nicotiana benthamiana plant deficient in xylosyltransferase activity
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AR078060A1 (en) 2009-07-14 2011-10-12 Novartis Ag DECONTAMINATION OF CONTAINER SURFACE PREVIOUSLY FILLED IN SECONDARY PACKAGING
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
HRP20200768T4 (en) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag PRODUCTION OF PROTEIN IN CELL GROWTH MEDIA WITHOUT GLUTAMINE
EP2464744A1 (en) 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biological markers for monitoring patient response to vegf antagonists
NZ598131A (en) 2009-08-15 2014-08-29 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US8642515B2 (en) 2009-09-04 2014-02-04 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
RU2012114094A (en) 2009-09-11 2013-10-20 Дженентек, Инк. METHOD FOR IDENTIFICATION OF A PATIENT WITH AN INCREASED PROBABILITY OF ANSWER TO ANTI-CANCER AGENT
AU2010297344A1 (en) 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
MX2012004306A (en) 2009-10-21 2012-04-30 Genentech Inc Genetic polymorphisms in age-related macular degeneration.
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
BR112012013093A2 (en) 2009-12-21 2017-12-12 Genentech Inc Stable aqueous pharmaceutical formulation, article, methods for stabilizing an antibody, for treating a disease or disorder in an individual, for reducing aggregation of a therapeutic monoclonal antibody and for manufacturing a pharmaceutical formulation, vial and stainless steel tank
EP2516465B1 (en) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antibodies and uses thereof
EP2519536A4 (en) 2009-12-29 2013-06-05 Reddys Lab Ltd Dr Protein purification by ion exchange
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
TWI619509B (en) 2010-02-23 2018-04-01 建南德克公司 Combination of carboplatin, paclitaxel and anti-VEGF antibodies in previously untreated stage III or IV ovarian, fallopian tube or primary peritoneal cancer
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (en) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents.
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
BR112012027828A2 (en) 2010-05-03 2016-08-09 Genentech Inc matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation
WO2011146394A1 (en) 2010-05-17 2011-11-24 Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
MX347225B (en) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Methods of treatment of pancreatic cancer.
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
RU2013104381A (en) 2010-07-02 2014-08-10 Дженентек, Инк. TREATMENT OF VASCULARIZED PIGMENT EPITELIUM EXTREMITATION THERAPY AGAINST VEGF
WO2012006503A1 (en) 2010-07-09 2012-01-12 Genentech, Inc. Anti-neuropilin antibodies and methods of use
KR20130126576A (en) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CA2805618A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
JP2013539364A (en) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR101910779B1 (en) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Fgfr1 extracellular domain combination therapies
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
CN103561771B (en) 2011-03-17 2019-01-04 伯明翰大学 redirected immunotherapy
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
JP6250533B2 (en) 2011-04-20 2017-12-20 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． Endoglin polypeptides and uses thereof
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
US9057728B2 (en) 2011-07-12 2015-06-16 Epitomics, Inc. FACS-based method for obtaining an antibody sequence
US9181532B2 (en) 2011-07-29 2015-11-10 Icon Genetics Gmbh Production of galactosylated N-glycans in plants
KR20140068877A (en) 2011-08-17 2014-06-09 제넨테크, 인크. Inhibition of angiogenesis in refractory tumors
LT3485903T (en) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
WO2013050155A1 (en) 2011-10-04 2013-04-11 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
BR112014008759A8 (en) * 2011-10-13 2017-09-12 Aerpio Therapeutics Inc TREATMENT OF EYE DISEASE
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
EP2788026A4 (en) 2011-12-05 2015-08-05 Univ Duke IMMUNOGENS V1V2
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
WO2013106765A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
DK2825558T3 (en) 2012-03-13 2019-07-22 Hoffmann La Roche Combination therapy for the treatment of ovarian cancer
BR112014023176B1 (en) 2012-03-27 2021-09-28 Genentech, Inc. METHODS OF PRODUCTION OF A RECOMBINANT PROTEIN
KR20140142719A (en) 2012-03-30 2014-12-12 제넨테크, 인크. Diagnostic methods and compositions for treatment of cancer
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
RU2689760C2 (en) 2012-05-31 2019-05-30 Дженентек, Инк. Methods of treating cancer using pd-1 axis binding and vegf antagonists
PL3777834T3 (en) 2012-06-01 2022-05-30 Novartis Ag Syringe
BR112014028376A2 (en) 2012-06-08 2018-04-24 Hoffmann La Roche methods for treating a hyperproliferative disorder, for determining compounds, for monitoring, for optimizing therapeutic efficacy and for identifying a biomarker; pharmaceutical formulation; use of a therapeutic combination and gdc-0032, article of manufacture, product and invention
DE202013000688U1 (en) 2012-07-03 2013-03-05 Novartis Ag Glass syringe
KR20150038593A (en) 2012-08-07 2015-04-08 제넨테크, 인크. Combination therapy for the treatment of glioblastoma
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
TW202037609A (en) 2012-11-01 2020-10-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
TW201427989A (en) 2012-12-18 2014-07-16 Novartis Ag Compositions and methods for long acting proteins
CA2898146C (en) 2012-12-19 2020-12-01 Charles Andrew BOSWELL Methods and compositions for radiohalogen protein labeling
WO2014110261A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
RS60026B1 (en) 2013-02-18 2020-04-30 Vegenics Pty Ltd Ligand binding molecules and uses thereof
CN110538322A (en) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 Antibody formulations
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
JP2016513478A (en) 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド Cell culture medium and method for producing antibodies
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (en) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг MODIFIED ANTIBODY TO CONTACT HUMAN FCRN AND METHODS OF ITS APPLICATION
SG10201703977UA (en) 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
KR101541478B1 (en) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 Anti-vegf antibodies and pharmaceutical composition comprising same for preventing, diagnosing or treating cancer or angiogenesis-related disease
BR112015032690B1 (en) 2013-06-25 2020-03-10 Vaccinex, Inc. USE OF SEMAPHORIN-4D INHIBITOR MOLECULES IN COMBINATION WITH AN IMMUNOMODULATIVE THERAPY TO INHIBIT TUMORAL GROWTH AND METASTASIS
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3851118A1 (en) 2013-10-25 2021-07-21 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
EP3071181B1 (en) 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
CN115504924A (en) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 Hydrazino-pyrrolo compounds and methods for producing conjugates
WO2015103139A1 (en) * 2013-12-31 2015-07-09 Development Center For Biotechnology Anti-vegf antibodies and use thereof
MX380658B (en) 2014-01-15 2025-03-11 Hoffmann La Roche REGION FC VARIANTS WITH ENHANCED PROTEIN A BINDING.
PE20170255A1 (en) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc ANTIBODY MOLECULES BINDING AND USES OF PD-1
HUE045065T2 (en) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antibody molecules and their uses
KR20160135190A (en) 2014-02-14 2016-11-25 앤드류 에스. 카이 Improved methods for the treatment of vascularizing cancers
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
EP3110941A4 (en) 2014-02-25 2017-10-18 Dr. Reddy's Laboratories Ltd. Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
PL3116891T3 (en) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
KR102442436B1 (en) 2014-03-14 2022-09-15 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
KR20160146747A (en) 2014-03-31 2016-12-21 제넨테크, 인크. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CN106456757A (en) 2014-05-12 2017-02-22 福尔密孔股份公司 Pre-filled plastic syringe containing VEGF antagonist
WO2015176033A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102486180B1 (en) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 Anti-her2 antibody-maytansine conjugates and methods of use thereof
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CN105330739B (en) * 2014-08-12 2020-12-25 中美华世通生物医药科技（武汉）有限公司 Antibody or antigen binding fragment thereof specifically bound with human vascular endothelial growth factor and application thereof
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CA2957717C (en) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
KR20170060042A (en) 2014-09-13 2017-05-31 노파르티스 아게 Combination therapies of alk inhibitors
CN106794247B (en) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 Antibody formulation
KR20170066546A (en) 2014-10-03 2017-06-14 노파르티스 아게 Combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
KR20210013299A (en) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
CA2959821C (en) 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
CR20170240A (en) 2014-11-10 2018-04-03 Genentech Inc ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN114306575A (en) 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 Treatment of age-related macular degeneration with small active choroidal neovascularisation
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
KR20170094165A (en) 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
MX2017009759A (en) * 2015-01-28 2017-10-27 Pfizer Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation.
EA201791982A1 (en) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY
CN107810197B (en) 2015-04-24 2022-10-25 豪夫迈·罗氏有限公司 Methods of identifying bacteria comprising binding polypeptides
JP2018514550A (en) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Treatment of PD-L1 negative melanoma using anti-PD-1 antibody and anti-CTLA-4 antibody
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
MX2017015937A (en) 2015-06-08 2018-12-11 Genentech Inc Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
EP3322731B1 (en) 2015-07-14 2021-01-13 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (en) 2015-07-29 2021-11-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CA2992660A1 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HU231463B1 (en) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Method for increasing the galactose content of recombinant proteins
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
CA2987644A1 (en) * 2015-08-21 2017-03-02 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CN116440279B (en) 2015-09-17 2026-02-24 伊缪诺金公司 Therapeutic combinations comprising anti-FOLR 1 immunoconjugates
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
DK3353196T5 (en) 2015-09-22 2024-09-30 Inst Nat Sante Rech Med POLYPEPTIDES CAPABLE OF INHIBITING THE BINDING BETWEEN LEPTIN AND NEUROPILIN-1
PE20181363A1 (en) 2015-09-23 2018-08-27 Genentech Inc OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
AU2016344133A1 (en) 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
PE20181326A1 (en) 2015-11-03 2018-08-20 Janssen Biotech Inc ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND ITS USES
EP3370764A4 (en) 2015-11-05 2019-07-17 The Regents of The University of California CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME
EP3373937B1 (en) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
CN108290004A (en) 2015-11-18 2018-07-17 福尔密孔股份公司 Prefilled plastic syringes containing VEGF antagonists
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
EP3377100B1 (en) 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
ES2986067T3 (en) 2015-12-17 2024-11-08 Novartis Ag Antibody molecules against PD-1 and their uses
KR20250057128A (en) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
EP3436610A1 (en) 2016-03-29 2019-02-06 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
KR20190003958A (en) 2016-04-15 2019-01-10 제넨테크, 인크. Treatment and monitoring of cancer
MX2018012493A (en) 2016-04-15 2019-06-06 Genentech Inc METHODS TO CONTROL AND TREAT CANCER.
LT3458053T (en) 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
JP2019524706A (en) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment
EP3481963B1 (en) 2016-07-08 2025-10-29 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
MA45674A (en) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co METHODS AND MATERIALS FOR EVALUATING A RESPONSE TO PLASMOBLAST AND PLASMOCYTE DEPLÉTION TREATMENTS
BR112019001206A2 (en) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc humanized monoclonal antibodies targeting ve-ptp (hptp-ss)
WO2018018613A1 (en) 2016-07-29 2018-02-01 广东东阳光药业有限公司 Cell culture medium and culture method for increasing purity of antibody
CN106222129A (en) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 A cell culture medium and culture method for improving antibody purity
AU2017311585A1 (en) 2016-08-12 2019-02-28 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
IL264961B2 (en) 2016-08-23 2025-02-01 Medimmune Ltd Anti-vegf-a antibodies and uses thereof
JPWO2018070390A1 (en) 2016-10-12 2019-08-22 第一三共株式会社 Composition comprising anti-ROBO4 antibody and other agent
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
TW201837467A (en) 2017-03-01 2018-10-16 美商建南德克公司 For the diagnosis and treatment of cancer
WO2018173075A1 (en) * 2017-03-24 2018-09-27 Council Of Scientific And Industrial Research A process for the purification of recombinant antibody fragments
JP2020515639A (en) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド PPARγ agonists for the treatment of progressive supranuclear palsy
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
JP7282689B2 (en) 2017-05-19 2023-05-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ Methods for Producing Refolded Recombinant Humanized Ranibizumab
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (en) 2017-06-14 2019-02-01 德商拜耳製藥公司 Non-antibody vegf antagonists for the treatment of neovascular glaucoma
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
EP3650045B1 (en) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
JP2021500355A (en) 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド Diagnostic methods for anti-angiogenic drug therapy
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
CN110003328B (en) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 Long-acting low-toxicity recombinant anti-VEGF humanized monoclonal antibody and production method thereof
KR20210006321A (en) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 Subcutaneous administration of anti-CD38 antibody
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
SG11202006712XA (en) 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. ANTI-IL-6 ANTIBODIES AND RELATED FUSION CONSTRUCTS AND CONJUGATES
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
KR102831159B1 (en) 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 Methods for preventing or treating side effects of cancer treatment
PE20211916A1 (en) 2018-05-24 2021-09-28 Janssen Biotech Inc BINDING AGENTS OF PSMA AND USES OF THEM
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TWI869346B (en) 2018-05-30 2025-01-11 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019229116A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
HRP20240584T1 (en) 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Methods of producing recombinant proteins
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN109053895B (en) 2018-08-30 2020-06-09 中山康方生物医药有限公司 Anti-PD-1-anti-VEGFA bifunctional antibody, pharmaceutical composition and use thereof
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
HU231514B1 (en) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. A method for changing the glycosylation pattern of a recombinant glycoprotein produced in cell culture
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN109134651B (en) * 2018-12-03 2019-02-22 上海复宏汉霖生物技术股份有限公司 A kind of monoclonal antibody of anti-vegf and its preparation method and application
WO2020118043A1 (en) 2018-12-07 2020-06-11 Coherus Biosciences, Inc. Methods for producing recombinant proteins
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
KR20210139329A (en) 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 Methods of anti-tumor therapy
TWI856084B (en) 2019-04-01 2024-09-21 美商建南德克公司 Compositions and methods for stabilizing protein-containing formulations
HU231498B1 (en) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Development of affinity chromatography of immunoglobulins using pre-binding flocculation
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. Recombinant elastin and production thereof
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
TW202532428A (en) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 Variant aav capsids for intravitreal delivery
CN114269376A (en) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 Methods of treating cancer with anti-PD-L1 antibodies
EP3965816A1 (en) 2019-05-06 2022-03-16 MedImmune Limited Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
CN114340735B (en) 2019-06-28 2024-11-12 璟尚生物制药公司 Antitumor antagonists composed of mutant TGFβ1-RII extracellular domain and immunoglobulin scaffold
EP4007808A1 (en) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CN114502590A (en) 2019-09-18 2022-05-13 诺华股份有限公司 ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072182A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
WO2021072210A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
PH12022551278A1 (en) 2019-11-25 2023-11-20 Akeso Biopharma Inc Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
JP7697961B2 (en) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A method for determining whether a subject has or is at risk for having central serous chorioretinopathy.
PE20230252A1 (en) 2020-03-13 2023-02-07 Genentech Inc ANTI-INTERLEUKIN-33 ANTIBODIES AND ITS USES FOR THEM
CN115916963A (en) 2020-03-27 2023-04-04 门德斯有限公司 Ex vivo use of leukemia-derived modified cells to enhance the efficacy of adoptive cell therapy
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
TW202216761A (en) 2020-07-16 2022-05-01 瑞士商諾華公司 Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CN114106190B (en) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 An anti-VEGF/PD-L1 bispecific antibody and its use
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2022074646A1 (en) 2020-10-05 2022-04-14 Protalix Ltd. Dicer-like knock-out plant cells
JP2023546359A (en) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
JP2023546112A (en) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
TWI886356B (en) 2020-11-13 2025-06-11 美商建南德克公司 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2024506249A (en) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ Methods of tumor vaccination
EP4284838A2 (en) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
EP4190819A4 (en) 2021-03-12 2024-08-14 Akeso Biopharma, Inc. PHARMACEUTICAL COMBINATION WITH BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY AND USE THEREOF
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
BR112023022439A2 (en) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc IMPLANTABLE DEVICE FOR SUSTAINED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
US20240252679A1 (en) 2021-05-28 2024-08-01 Shanghai Regenelead Therapies Co., Ltd. Recombinant adeno-associated virus having variant capsid, and application thereof
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
CN118043350A (en) 2021-08-13 2024-05-14 信达生物制药(苏州)有限公司 Anti-VEGF A and VEGF C bispecific antibodies and uses thereof
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
JPWO2023144973A1 (en) 2022-01-27 2023-08-03
KR20240144944A (en) 2022-01-28 2024-10-04 온퀄리티 파마슈티컬스 차이나 리미티드 Methods for preventing or treating diseases or symptoms associated with antineoplastic agents
TW202342525A (en) 2022-02-02 2023-11-01 美商阿科奧斯公司 Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
JP2025505812A (en) 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド Compounds and their uses
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
CN117679505A (en) 2022-09-09 2024-03-12 中山康方生物医药有限公司 Drug combinations and uses
KR20250167153A (en) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. Anti-stem cell factor (SCF) and anti-thymic stromal lymphopoietin (TSLP) antibodies, and bispecific constructs
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025157267A1 (en) * 2024-01-25 2025-07-31 中山康方生物医药有限公司 Pharmaceutical use of anti-pd-1-anti-vegfa bispecific antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB2268744A (en) * 1989-12-21 1994-01-19 Celltech Ltd Recombinant antibody having anti-CD3 binding specificity

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS6289971A (en) * 1985-06-13 1987-04-24 Toray Ind Inc Liquid developer for electrostatic latent image
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0397834B1 (en) * 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
ATE414768T1 (en) 1991-04-10 2008-12-15 Scripps Research Inst LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU687727B2 (en) * 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
DK0752248T3 (en) 1992-11-13 2000-11-13 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antibody
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
KR100816621B1 (en) * 1997-04-07 2008-03-24 제넨테크, 인크. Anti-VEGF Antibodies
PT971959E (en) * 1997-04-07 2006-05-31 Genentech Inc HUMANIZED ANTIBODIES AND METHODS FOR FORMING HUMANIZED ANTIBODIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268744A (en) * 1989-12-21 1994-01-19 Celltech Ltd Recombinant antibody having anti-CD3 binding specificity
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM ET AL.,: "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", NATURE, vol. 362, 1993, London, GB, pages 841, XP002013864 *
M. BACA ET AL.,: "Antibody humanization using monovalent phage display", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 16, 18 April 1997 (1997-04-18), pages 10678 - 10684, XP002077471 *
M.M. BENDIG: "Humanization of rodent monoclonal antibodies", METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, vol. 8, 1995, New York, NY, US, pages 83 - 93, XP000647344 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US8951791B2 (en) 2003-02-03 2015-02-10 Ibio, Inc. System for expression of genes in plants
US9551001B2 (en) 2003-02-03 2017-01-24 Ibio, Inc. System for expression of genes in plants
US9012199B2 (en) 2003-05-22 2015-04-21 Ibio, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US8187597B2 (en) 2003-08-27 2012-05-29 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US8685397B2 (en) 2003-08-27 2014-04-01 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9308180B2 (en) 2005-08-31 2016-04-12 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US11814425B2 (en) 2006-04-07 2023-11-14 Eye Point Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
USRE47194E1 (en) 2007-05-08 2019-01-08 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US8945580B2 (en) 2007-07-11 2015-02-03 Ibio Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US10927163B2 (en) 2007-12-21 2021-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9983213B2 (en) 2008-07-23 2018-05-29 Roche Diagnostics Operations, Inc. Identification of subjects being susceptible to anti-angiogenesis therapy
US9115201B2 (en) 2008-09-28 2015-08-25 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US11993642B2 (en) 2009-04-07 2024-05-28 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US9487809B2 (en) 2010-05-28 2016-11-08 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US10011856B2 (en) 2010-05-28 2018-07-03 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US11046987B2 (en) 2010-05-28 2021-06-29 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US10704071B2 (en) 2010-05-28 2020-07-07 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US9487589B2 (en) 2011-06-30 2016-11-08 Genentech, Inc. Anti-c-met-antibody formulations
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer
US11945837B2 (en) 2011-12-22 2024-04-02 Genentech, Inc. Ion exchange membrane chromatography
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10421984B2 (en) 2012-09-19 2019-09-24 Genentech, Inc. Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
US11015214B2 (en) 2012-09-19 2021-05-25 Genentech, Inc. Microorganisms comprising a mutant metA allele for reducing norleucine misincorporation into proteins
US10179925B2 (en) 2012-09-19 2019-01-15 Genentech, Inc. Compositions for preventing norleucine misincorporation into proteins
US9579390B2 (en) 2012-11-12 2017-02-28 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US11273171B2 (en) 2013-07-12 2022-03-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US12016875B2 (en) 2013-07-12 2024-06-25 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US11590235B2 (en) 2013-09-08 2023-02-28 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10602739B2 (en) 2014-07-09 2020-03-31 Genentech, Inc. PH adjustment to improve thaw recovery of cell banks
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US11999801B2 (en) 2014-12-03 2024-06-04 Hoffman-La Roche Inc. Multispecific antibodies
US11820816B2 (en) 2017-12-29 2023-11-21 Hoffman-La Roche Inc. Anti-VEGF antibodies and methods of use
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US12168036B2 (en) 2018-05-10 2024-12-17 Regeneron Pharmaceuticals, Inc. Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
US11873334B2 (en) 2018-09-24 2024-01-16 EyePoint Pharmaceuticals, Inc. Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US12398204B2 (en) 2018-09-24 2025-08-26 EyePoint Pharmaceuticals, Inc. Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist

Also Published As

Publication number Publication date
CY1106382T1 (en) 2010-07-28
DK1325932T3 (en) 2005-05-30
CA2286330A1 (en) 1998-10-15
BR9809387A (en) 2001-09-11
EP1325932B1 (en) 2005-04-20
EP1650220B1 (en) 2007-09-05
EP1325932B9 (en) 2006-07-19
JP3957765B2 (en) 2007-08-15
IL132240A0 (en) 2001-03-19
TR199903123T2 (en) 2000-05-22
CA2286330C (en) 2008-06-10
BRPI9809387B1 (en) 2016-11-22
AU7100798A (en) 1998-10-30
ATE293640T1 (en) 2005-05-15
LU91167I2 (en) 2005-06-20
NO324264B1 (en) 2007-09-17
CY2005008I2 (en) 2017-11-14
DE122007000021I1 (en) 2007-05-24
DK1325932T5 (en) 2005-10-03
NO994869D0 (en) 1999-10-06
CN1259962A (en) 2000-07-12
EP1650220A3 (en) 2006-05-03
DE69829891T2 (en) 2005-10-06
EP1325932A3 (en) 2003-10-29
EP1787999B1 (en) 2010-08-04
KR100870353B1 (en) 2008-11-25
DE122005000026I1 (en) 2005-08-04
LU91320I2 (en) 2007-04-30
BRPI9809387B8 (en) 2021-05-25
NL300278I1 (en) 2007-06-01
EP1650220A2 (en) 2006-04-26
GEP20105118B (en) 2010-11-25
DE69836729D1 (en) 2007-02-08
NO2007015I1 (en) 2008-01-14
ATE349470T1 (en) 2007-01-15
NL300193I1 (en) 2005-07-01
NO2007015I2 (en) 2011-11-28
EP1325932A2 (en) 2003-07-09
CN100480269C (en) 2009-04-22
EP0973804A2 (en) 2000-01-26
US7060269B1 (en) 2006-06-13
NO994869L (en) 1999-12-06
CY2007012I2 (en) 2009-11-04
NO2007014I2 (en) 2011-02-21
KR20080003453A (en) 2008-01-07
DK0973804T3 (en) 2007-05-07
US7297334B2 (en) 2007-11-20
CY2005008I1 (en) 2009-11-04
HK1023577A1 (en) 2000-09-15
NO2007014I1 (en) 2008-01-14
LU91320I9 (en) 2018-12-31
CY2007012I1 (en) 2009-11-04
PT1325932E (en) 2005-06-30
FR07C0017I2 (en) 2008-05-09
FR05C0020I2 (en) 2008-05-09
ES2273415T3 (en) 2007-05-01
JP2001509817A (en) 2001-07-24
EP1787999A1 (en) 2007-05-23
FR07C0017I1 (en) 2007-04-27
KR100816621B1 (en) 2008-03-24
LTPA2005005I1 (en) 2017-11-27
AU743758B2 (en) 2002-02-07
DE69829891D1 (en) 2005-05-25
NZ500078A (en) 2001-10-26
HK1084402A1 (en) 2006-07-28
EP0973804B1 (en) 2006-12-27
ES2236634T3 (en) 2005-07-16
US20050112126A1 (en) 2005-05-26
NL300278I2 (en) 2007-10-01
DE122005000050I1 (en) 2005-12-29
FR05C0020I1 (en) 2005-05-27
KR20080003452A (en) 2008-01-07
SI1325932T1 (en) 2005-08-31
DE69836729T2 (en) 2007-12-13
NL300193I2 (en) 2005-10-03
WO1998045331A2 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
WO1998045331A3 (en) Anti-vegf antibodies
EP2336190A3 (en) Anti-VEGF antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 132240

Country of ref document: IL

Ref document number: 98805914.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 71007/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2286330

Country of ref document: CA

Ref document number: 2286330

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 500078

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1998 542922

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/009182

Country of ref document: MX

Ref document number: 1019997009194

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998917991

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1999/03123

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998917991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997009194

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 71007/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998917991

Country of ref document: EP